CN1950077A - 利用过氧化物酶体增殖物激活受体－δ激动剂治疗多发性硬化和其他脱髓鞘病 - Google Patents

利用过氧化物酶体增殖物激活受体－δ激动剂治疗多发性硬化和其他脱髓鞘病 Download PDF

Info

Publication number
CN1950077A
CN1950077A CNA2005800148506A CN200580014850A CN1950077A CN 1950077 A CN1950077 A CN 1950077A CN A2005800148506 A CNA2005800148506 A CN A2005800148506A CN 200580014850 A CN200580014850 A CN 200580014850A CN 1950077 A CN1950077 A CN 1950077A
Authority
CN
China
Prior art keywords
ppar
cells
disease
multiple sclerosis
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800148506A
Other languages
English (en)
Chinese (zh)
Inventor
K·尚德罗斯
J·梅里尔
A·明尼克
李岚
O·霍克瓦
刘云
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Publication of CN1950077A publication Critical patent/CN1950077A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA2005800148506A 2004-04-01 2005-03-29 利用过氧化物酶体增殖物激活受体－δ激动剂治疗多发性硬化和其他脱髓鞘病 Pending CN1950077A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55853304P 2004-04-01 2004-04-01
US60/558,533 2004-04-01

Publications (1)

Publication Number Publication Date
CN1950077A true CN1950077A (zh) 2007-04-18

Family

ID=34977094

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800148506A Pending CN1950077A (zh) 2004-04-01 2005-03-29 利用过氧化物酶体增殖物激活受体－δ激动剂治疗多发性硬化和其他脱髓鞘病

Country Status (16)

Country Link
US (1) US20070149580A1 (https=)
EP (1) EP1737440A2 (https=)
JP (1) JP2007530703A (https=)
KR (1) KR20060134191A (https=)
CN (1) CN1950077A (https=)
AU (1) AU2005231358A1 (https=)
BR (1) BRPI0509540A (https=)
CA (1) CA2561159A1 (https=)
IL (1) IL178165A0 (https=)
MA (1) MA28561B1 (https=)
MX (1) MXPA06011218A (https=)
NO (1) NO20064985L (https=)
RU (1) RU2006138495A (https=)
SG (1) SG138623A1 (https=)
WO (1) WO2005097098A2 (https=)
ZA (1) ZA200607850B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005024384D1 (de) 2004-05-05 2010-12-09 High Point Pharmaceuticals Llc Neue verbindungen, ihre herstellung und verwendung
US8053598B2 (en) 2004-05-05 2011-11-08 High Point Pharmaceuticals, Llc Compounds, their preparation and use
ES2372617T3 (es) 2005-06-30 2012-01-24 High Point Pharmaceuticals, Llc Ácidos fenoxiacéticos como activadores de ppar-delta.
EP1964575B1 (en) * 2005-11-28 2015-09-23 Senju Pharmaceutical Co., Ltd. Pharmaceutical comprising ppar agonist
CN103224477A (zh) 2005-12-22 2013-07-31 高点制药有限责任公司 作为PPAR-δ活化剂的苯氧基乙酸
US7943612B2 (en) 2006-03-09 2011-05-17 High Point Pharmaceuticals, Llc Compounds that modulate PPAR activity, their preparation and use
US8716317B2 (en) 2008-06-09 2014-05-06 Sanofi Sulfonamides with heterocycle and oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
US8329725B2 (en) 2008-06-09 2012-12-11 Sanofi Annelated pyrrolidin sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
EP2483406A2 (en) 2009-09-30 2012-08-08 President and Fellows of Harvard College Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products
KR20120107113A (ko) 2009-12-17 2012-09-28 사노피 수초 염기성 단백질 프로모터(ｍｂｐ-ｌｕｃｉ)의 조절 하에 루시페라제를 발현하는 동물 모델 및 생물발광 생체내 영상화를 위한 상기 동물 모델의 용도
JP6133790B2 (ja) * 2011-02-18 2017-05-24 ザ スクリプス リサーチ インスティテュート ミエリン形成細胞運命へのオリゴデンドロサイト前駆細胞の定方向分化
EP3756661A1 (en) 2013-09-09 2020-12-30 vTv Therapeutics LLC Use of a ppar-delta agonist for treating muscle atrophy
WO2021092279A1 (en) * 2019-11-06 2021-05-14 Board Of Regents, The University Of Texas System Methods for the treatment of dysmyelinating/demyelinating diseases
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1856997A (en) * 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
AU2001288271A1 (en) * 2000-08-17 2002-02-25 Harrihar A. Pershadsingh Methods for treating inflammatory diseases
GB0024362D0 (en) * 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
GB0024361D0 (en) * 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
WO2004082621A2 (en) * 2003-03-15 2004-09-30 Bethesda Pharmaceuticals, Inc. Novel ppar agonists, pharmaceutical compositions and uses thereof
JPWO2004093910A1 (ja) * 2003-04-22 2006-07-13 アステラス製薬株式会社 ＰＰＡＲδアゴニストによる脳神経変性疾患治療剤

Also Published As

Publication number Publication date
WO2005097098A2 (en) 2005-10-20
BRPI0509540A (pt) 2007-09-18
MXPA06011218A (es) 2007-01-16
KR20060134191A (ko) 2006-12-27
JP2007530703A (ja) 2007-11-01
ZA200607850B (en) 2008-10-29
IL178165A0 (en) 2008-03-20
EP1737440A2 (en) 2007-01-03
CA2561159A1 (en) 2005-10-20
NO20064985L (no) 2006-10-31
WO2005097098A3 (en) 2005-12-22
RU2006138495A (ru) 2008-05-10
US20070149580A1 (en) 2007-06-28
MA28561B1 (fr) 2007-04-03
SG138623A1 (en) 2008-01-28
AU2005231358A1 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
CN1950077A (zh) 利用过氧化物酶体增殖物激活受体－δ激动剂治疗多发性硬化和其他脱髓鞘病
AU765528C (en) Compositions and methods for the treatment of alzheimer's disease, central nervous system injury, and inflammatory diseases
CN1222523C (zh) 作为amp－特异性磷酸二酯酶抑制剂的3－噻唑－4－基－吡咯烷衍生物
US20090275621A1 (en) 1, 3, 4-oxadiazol-2-ones as ppar delta modulators and their use thereof
CN1429267A (zh) 神经祖细胞群体
CN1638765A (zh) Hedgehog信号转导途径介质、其相关组合物以及应用
CN1543500A (zh) 从人多能干细胞产生心肌细胞系细胞
CN101037438A (zh) 用作gsk－3的抑制剂的吡唑组合物
CN1625410A (zh) 2,4,6－三氨基－1,3,5－三嗪衍生物
CN1612869A (zh) 作为黑素皮质素受体调节剂的新的1，2，4－噻二唑鎓衍生物
CN1671835A (zh) 一种建立多能人胚泡衍生的干细胞的方法
CN1494422A (zh) Gabaa反相激动剂与烟碱受体不完全激动剂、雌激素、选择性雌激素调节剂、或维生素e联合用于认知障碍的用途
CN1617862A (zh) 作为黑素皮质素受体调节剂的新的1，2，4－噻二唑衍生物
CN1863904A (zh) 由干细胞分化诱导心肌细胞的方法
HK1045528B (zh) 神经营养生长因子
US7132287B2 (en) Method for neural stem cell differentiation using 5HT-1A agonists
US20170196839A1 (en) Neurodegenerative diseases and methods of modeling
US7576109B2 (en) 1,3,4-oxadiazol-2-ones as PPAR delta modulators and their use thereof
HK1102384A (en) Use of peroxisome proliferator activated receptor delta agonists for the treatment of ms and other demyelinating diseases
WO2021141452A1 (ko) 인슐린 생산세포로의 분화 유도용 조성물 및 이의 이용
CN101060863A (zh) 疼痛的治疗和预防中神经胶质细胞来源的bdnf的调节
CN1842590A (zh) 从灵长类动物的胚胎干细胞向造血细胞的分化方法
CN1934095A (zh) 离子通道调节剂
CN1708318A (zh) 角膜疾病治疗剂
CN101048160A (zh) 嘌呤和嘧啶cdk抑制剂及其用于治疗自身免疫性疾病

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1102384

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20070418

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1102384

Country of ref document: HK